Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bioventus Inc. (BVS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered summaries to help interpret key points. As a Nasdaq Global Select Market issuer of Class A common stock, Bioventus files current reports on Form 8-K and other periodic reports that provide insight into its operations, governance and capital structure.
In its Form 8-K filings, Bioventus reports material events such as quarterly and year-to-date financial results, including net sales by business (Pain Treatments, Surgical Solutions and Restorative Therapies), net income and the use of non-GAAP measures like Adjusted EBITDA and non-GAAP earnings. These filings often reference accompanying press releases furnished as exhibits, which our AI tools can summarize to highlight segment performance and notable drivers.
Bioventus also uses Form 8-K to disclose financing arrangements, such as the 2025 Credit Agreement that established a $300 million term loan facility and a $100 million revolving credit facility. The filing details interest rate terms, leverage and coverage covenants, maturity dates and the use of proceeds to refinance prior credit facilities. AI analysis can help readers quickly understand how such agreements affect liquidity, leverage and future obligations.
Additional 8-K items cover governance changes, including the appointment of new directors under the terms of a Stockholders Agreement with certain major stockholders. These disclosures explain board composition, designation rights and whether directors receive compensation from the company.
On this page, users can access Bioventus 10-K annual reports, 10-Q quarterly reports, 8-K current reports and Form 4 insider transaction filings as they become available from EDGAR. Real-time updates and AI-generated explanations are designed to make complex filings more accessible, whether you are reviewing segment disclosures, credit facility terms or board changes related to BVS.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported routine equity compensation activity in the form of restricted stock units. On March 20, 2026, he exercised 18,625 RSUs, receiving the same number of shares of Class A common stock at a stated price of $0.00 per share.
To cover tax obligations related to this vesting, 8,091 shares of Class A common stock were withheld at $8.64 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, Singleton directly held 169,981 shares of Class A common stock.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported multiple equity compensation transactions in company stock. He received 104,000 restricted stock units and a stock option for 116,000 shares of Class A common stock at an exercise price of $8.6200 per share, both granted on March 13, 2026. He also reported earlier grants from March 14, 2025 of 54,000 RSUs and a stock option for 61,000 shares at $9.6100 per share. On the same 2026 date, he exercised 13,500 RSUs into 13,500 shares of Class A common stock, with 5,865 shares withheld to cover tax obligations. After these transactions, he directly holds 159,447 shares of Class A common stock. The RSUs and options vest in four equal annual installments starting on March 15, 2025 and March 15, 2026, subject to his continued service.
Bioventus Inc. senior vice president and chief compliance officer Katrina J. Church received new equity awards and exercised existing awards. On March 13, 2026 she was granted 24,000 restricted stock units and 27,000 stock options with an exercise price of $8.62 per share, all vesting in four annual installments starting March 15, 2026, subject to continued service.
Church also exercised a total of 6,955 restricted stock units into Class A common stock, with 3,022 shares withheld to cover tax obligations. After these transactions she directly holds 61,732 shares of Class A common stock, plus outstanding RSU and option awards disclosed in the filing.
Bioventus Inc. senior vice president and general counsel Anthony D'Adamio reported multiple equity compensation transactions in Class A common stock and related derivatives. On March 13, 2026, he received grants of 83,000 restricted stock units (RSUs) and 92,000 stock options with an exercise price of $8.62 per share, expiring on March 13, 2036. Each RSU represents a right to receive one share of Class A common stock. The RSUs and options granted in 2025 and 2026 vest in four equal annual installments beginning on March 15, 2025 and March 15, 2026, subject to his continued service. On the same 2026 date, he exercised 8,886 and 8,750 RSUs into the same number of Class A shares, and the company withheld 3,861 and 3,802 shares at a price of $8.62 per share to cover tax obligations. Following these transactions, he directly owned 148,042 shares of Bioventus Class A common stock.
Bioventus Inc. President and CEO Robert E. Claypoole reported equity compensation changes and an option-related share delivery. On March 13, 2026, he exercised 33,500 restricted stock units into 33,500 shares of Class A common stock at $0.00 per share and had 14,553 shares withheld at $8.62 per share to cover tax obligations, leaving 135,944 Class A shares held directly.
On the same date, he received grants of 278,000 restricted stock units and 309,000 stock options for Class A common stock, with the options carrying an exercise price of $8.62 and expiring on March 13, 2036. Footnotes state that the RSUs and options granted in 2025 and 2026 vest in four equal annual installments starting on the first four anniversaries of March 15, 2025 and March 15, 2026, subject to his continued service.
Bioventus Inc. director Michelle McMurry-Heath reported an open-market sale of 12,000 shares of Class A common stock. The shares were sold at a weighted average price of $8.7866, in multiple trades between $8.73 and $8.81. After the transaction, she directly holds 44,997 shares.
BVS submitted a Form 144 reporting proposed sales of Class A shares. The filing lists Fidelity Brokerage Services LLC as broker and shows a line item of 12,000 Class A shares with an aggregate amount of $105,720.00 and an identifier 67368052, dated 03/11/2026 on NASDAQ. The notice also itemizes restricted stock vesting entries: 7,443 shares on 06/06/2023, 386 shares on 06/16/2023, and 4,171 shares on 06/07/2024.
Bioventus Inc. is a global medical device company focused on relieving pain and treating musculoskeletal conditions through three businesses: Pain Treatments, Surgical Solutions and Restorative Therapies. In 2025, its U.S. and International segments generated 88% and 12% of total net sales, respectively.
The company highlights growth plans to strengthen leading positions in hyaluronic acid knee osteoarthritis injections, bone graft substitutes and EXOGEN fracture care, expand its Ultrasonics platform, and grow internationally. It also emphasizes new peripheral nerve stimulation products TalisMann and StimTrial, which received FDA 510(k) clearances in July 2025.
The filing includes an extensive risk summary covering leverage under a 2025 Credit Agreement, potential capital needs, litigation exposure, dependence on a limited product set, reimbursement and pricing pressures, regulatory and cybersecurity risks, and future loss of emerging growth company reporting benefits.
Bioventus Inc. reported a strong turnaround for 2025, moving from a prior-year loss to profitability and guiding to further growth in 2026. Fourth-quarter 2025 revenue was $157.9 million, up 2.8% reported and 10.0% on an organic basis, with GAAP earnings of $0.21 per diluted share and non-GAAP earnings of $0.24.
For full-year 2025, revenue was $568.1 million, down 0.9% reported but up 7.5% organically after divesting the Advanced Rehabilitation Business. Net income attributable to Bioventus was $22.7 million versus a $36.1 million loss last year, and Adjusted EBITDA rose 6.8% to $116.3 million. Adjusted EPS increased 21.4% to $0.68.
The company generated $74.7 million of cash from operations in 2025, up 92%, and reduced debt by $29 million in the fourth quarter, strengthening its balance sheet. For 2026, Bioventus expects net sales of $600–$610 million (about 6–7% growth), Adjusted EPS of $0.73–$0.77 (about 7–13% growth), and cash from operations of $82–$87 million.
Bioventus Inc. SVP & CFO Mark Leonard Singleton reported RSU vesting and related share movements. On February 15, 2026, 20,153 Restricted Stock Units were converted into 20,153 shares of Class A common stock at $0.00 per share.
Each RSU represents a right to receive one share of Class A common stock. To cover tax obligations, 9,429 Class A shares were disposed of at $8.27 per share in a tax-withholding transaction. After these transactions, Singleton directly owned 151,812 shares of Class A common stock and 40,304 RSUs, subject to time-based vesting conditions tied to continued service.